吉西他滨联合多西他赛对比多柔比星一线治疗晚期软组织肉瘤的III期随机对照试验(GeDDiS)
GeDDiS是一项在24家英国医院和1家瑞士SAKK医院开展的随机对照III期试验,比较吉西他滨联合多西他赛与多柔比星一线治疗晚期或转移性软组织肉瘤。结论认为多柔比星应继续作为大多数晚期软组织肉瘤患者的标准一线治疗。
要点
- 多柔比星应继续作为大多数晚期软组织肉瘤患者的标准一线治疗。
核心结论
- 多柔比星应继续作为大多数晚期软组织肉瘤患者的标准一线治疗。
- 结果为临床医生与患者选择局部晚期或转移性软组织肉瘤一线治疗提供证据参考。
研究设计与样本
- GeDDiS是一项随机对照III期试验,在24家英国医院和1家瑞士SAKK医院开展。
- 纳入组织学确诊的Trojani 2或3级局部晚期或转移性软组织肉瘤患者,入组前有疾病进展,且既往未接受肉瘤化疗或任何癌症的多柔比星治疗。
- 257例患者按1:1随机分配至多柔比星组(129例)或吉西他滨联合多西他赛组(128例)。
- 随机化按年龄(≤18岁 vs >18岁)和组织学亚型分层,采用含随机元素的最小化算法分配。
- 主要终点为意向治疗人群24周时存活且无进展的比例。
主要发现
- 最常见3-4级不良事件:中性粒细胞减少多柔比星组32/128(25%) vs 吉西他滨联合多西他赛组25/126(20%);发热性中性粒细胞减少26/128(20%) vs 15/126(12%);乏力8/128(6%) vs 17/126(14%);口腔黏膜炎18/128(14%) vs 2/126(2%);疼痛10/128(8%) vs 13/126(10%)。
- 最常见严重不良事件:发热性中性粒细胞减少多柔比星组27/155(17%) vs 吉西他滨联合多西他赛组15/130(12%);发热18/155(12%) vs 19/130(15%);中性粒细胞减少22/155(14%) vs 10/130(8%)。
- 意向治疗人群死亡154/257(60%):多柔比星组74/129(57%) vs 吉西他滨联合多西他赛组80/128(63%);无治疗相关死亡,2例死亡归因于疾病进展与治疗联合作用。
关键数值与推荐
- 多柔比星组给药方案:静脉多柔比星75 mg/m2,第1天,每3周一次,共6周期。
- 吉西他滨联合多西他赛组给药方案:静脉吉西他滨675 mg/m2第1天和第8天,静脉多西他赛75 mg/m2第8天,每3周一次,共6周期。
临床怎么用
- 多柔比星应继续作为大多数晚期软组织肉瘤患者的标准一线治疗。
- 选择局部晚期或转移性软组织肉瘤一线治疗时,这些结果可供临床医生与患者共同考虑。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma. METHODS: The GeDDiS trial was a randomised controlled phase 3 trial done in 24 UK hospitals and one Swiss Group for Clinical Cancer Research (SAKK) hospital. Eligible patients had histologically confirmed locally advanced or metastatic soft-tissue sarcoma of Trojani grade 2 or 3, disease progression before enrolment, and no previous chemotherapy for sarcoma or previous doxorubicin for any cancer. Patients were randomly assigned 1:1 to receive six cycles of intravenous doxorubicin 75 mg/m2 on day 1 every 3 weeks, or intravenous gemcitabine 675 mg/m2 on days 1 and 8 and intravenous docetaxel 75 mg/m2 on day 8 every 3 weeks. Treatment was assigned using a minimisation algorithm incorporating a random element. Randomisation was stratified by age (≤18 years vs >18 years) and histological subtype. The primary endpoint was the proportion of patients alive and progression free at 24 weeks in the intention-to-treat population. Adherence to treatment and toxicity were analysed in the safety population, consisting of all patients who received at least one dose of their randomised treatment. The trial was registered with the European Clinical Trials (EudraCT) database (no 2009-014907-29) and with the International Standard Randomised Controlled Trial registry (ISRCTN07742377), and is now closed to patient entry. FINDINGS: Between Dec 3, 2010, and Jan 20, 2014, 257 patients were enrolled and randomly assigned to the two treatment groups (129 to doxorubicin and 128 to gemcitabine and docetaxel). Median follow-up was 22 months (IQR 15·7-29·3). The proportion of patients alive and progression free at 24 weeks did not differ between those who received doxorubicin versus those who received gemcitabine and docetaxel (46·3% [95% CI 37·5-54·6] vs 46·4% [37·5-54·8]); median progression-free survival (23·3 weeks [95% CI 19·6-30·4] vs 23·7 weeks [18·1-20·0]; hazard ratio [HR] for progression-free survival 1·28, 95% CI 0·99-1·65, p=0·06). The most common grade 3 and 4 adverse events were neutropenia (32 [25%] of 128 patients who received doxorubicin and 25 [20%] of 126 patients who received gemcitabine and docetaxel), febrile neutropenia (26 [20%] and 15 [12%]), fatigue (eight [6%] and 17 [14%]), oral mucositis (18 [14%] and two [2%]), and pain (ten [8%] and 13 [10%]). The three most common serious adverse events, representing 111 (39%) of all 285 serious adverse events recorded, were febrile neutropenia (27 [17%] of 155 serious adverse events in patients who received doxorubicin and 15 [12%] of 130 serious adverse events in patients who received gemcitabine and docetaxel, fever (18 [12%] and 19 [15%]), and neutropenia (22 [14%] and ten [8%]). 154 (60%) of 257 patients died in the intention-to-treat population: 74 (57%) of 129 patients in the doxorubicin group and 80 (63%) of 128 in the gemcitabine and docetaxel group. No deaths were related to the treatment, but two deaths were due to a combination of disease progression and treatment. INTERPRETATION: Doxorubicin should remain the standard first-line treatment for most patients with advanced soft-tissue sarcoma. These results provide evidence for clinicians to consider with their patients when selecting first-line treatment for locally advanced or metastatic soft-tissue sarcoma. FUNDING: Cancer Research UK, Sarcoma UK, and Clinical Trial Unit Kantonsspital St Gallen.
引用
- Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017. PMID: 28882536. doi:10.1016/S1470-2045(17)30622-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。